Study #2016-0785
A Phase II Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients with High-Risk CLL
MD Anderson Study Status
Enrolling
Treatment Agent
Ibrutinib, Venetoclax
Description
This phase II trial studies how well venetoclax and ibrutinib work in treating participants with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and ibrutinib may work better in treating participants with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Information and next steps
Disease:
BTK Gene Mutation, Chronic Lymphocytic Leukemia, PLCG2 Gene Mutation, Small Lymphocytic Lymphoma
Study phase:
II
Physician name:
Philip Thompson
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help us #endcancer
Give Now
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.